Abstract
Studies have demonstrated that all 3 of the FDA-approved COVID-19 vaccines (Pfizer-BioNTech, Moderna, and Johnson & Johnson) are effective at reducing SARS-CoV-2-related hospitalizations, severe disease, and death. While these vaccinations have demonstrated a compelling safety profile, no discussion regarding the impact of COVID-19 vaccination on the exacerbation of slow-flow vascular malformations (SFVMs) has been had. We present the first case series of 3 consecutive patients who demonstrated clinical emergence or exacerbation of venous malformation status-post COVID-19 vaccination. As trauma, infection, and systemic inflammation can contribute to exacerbation of these vascular anomalies, COVID-19 vaccination may contribute to the clinical emergence and exacerbation of vascular malformations in patients with initial subclinical presentation.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call